However, another study opposed this and demonstrated that improved survival of glioblastoma patients benefiting from metronomic temozolomide (TMZ)-based therapies and indicating an overexpression of EGFR is associated with an activated EGFR/PI3K/Akt pathway independent of the presence or absence of EGFRvIII [46]. This evidence concerns the gene EGFR and glioblastoma.